Ranbaxy Laboratories Arm Launches Atorvastatin Tablets In Australian Market (21-Feb-2012)
Ranbaxy Laboratories' subsidiary-Ranbaxy Australia Pty (RAPL)- has launched Atorvastatin 10mg, 20mg, 40mg and 80mg tablets in the Australian market, after receiving approval from the Therapeutic Goods Administration (TGA), the regulatory authority in Australia.
The company has introduced the product under the brand name 'Trovas' and the drug will be available in bottles and blister packs, through retail pharmacy chains. Atorvastatin, a cholesterol reducing drug, is the most prescribed statin in Australia and represents the largest patent expiry opportunity ever, in the Australian pharmaceuticals market.
Ranbaxy Laboratories is India's largest pharmaceutical company. The company has global presence in 49 countries and is ranked amongst top ten global generics companies. Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.
Top News Today
 Aditya Birla Group Company - Idea Cellular has slashed 3G tariffs by up to 70%. As per the revision, Idea prepaid and postpaid users have to pay 3 paise per 10 KB of data against earlier levels of 10 paise
 National Thermal Power Corporation (NTPC) will be signing the fuel supply agreements' (FSA) with Coal India for 4,300 megawatts on 2009 terms. In these FSAs companies have change trigger level, which has
 After cellular market leader Bharti Airtel launched its 4G services, now Reliance Industries is reportedly gearing up to launch the services soon and has accordingly partnered with Himachal Futuristic
|
International Stock News
 US markets made a mixed closing on Tuesday, just a day after a buoyant rally, as concerns about Greece's potential exit from the eurozone resurfaced in the final hour. Though, the markets remained in jubilant
 US markets got a good bounce back on Monday with all major indices gaining more than 1%, it was one of the best session of the month. There was some M&A activity along with report that Chinese government
 US markets declined further on Friday, making it the worst week for the markets in 2012, as the most awaited Facebook (FB) IPO was only able to muster a slight gain in its public debut, while the eurozone
|
|
|